BR112022025969A2 - Adjuvante com atividade agonista de tlr4 - Google Patents

Adjuvante com atividade agonista de tlr4

Info

Publication number
BR112022025969A2
BR112022025969A2 BR112022025969A BR112022025969A BR112022025969A2 BR 112022025969 A2 BR112022025969 A2 BR 112022025969A2 BR 112022025969 A BR112022025969 A BR 112022025969A BR 112022025969 A BR112022025969 A BR 112022025969A BR 112022025969 A2 BR112022025969 A2 BR 112022025969A2
Authority
BR
Brazil
Prior art keywords
adjuvant
agonist activity
tlr4 agonist
compound
vaccine adjuvant
Prior art date
Application number
BR112022025969A
Other languages
English (en)
Inventor
Ban Hitoshi
Imazaki Yusuke
Takanashi Yosuke
Fukushima Akihisa
Original Assignee
Sumitomo Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Pharma Co Ltd filed Critical Sumitomo Pharma Co Ltd
Publication of BR112022025969A2 publication Critical patent/BR112022025969A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
    • C07H5/04—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
    • C07H5/06—Aminosugars
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/24—Condensed ring systems having three or more rings
    • C07H15/248—Colchicine radicals, e.g. colchicosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C07H1/06—Separation; Purification
    • C07H1/08—Separation; Purification from natural products
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

ADJUVANTE COM ATIVIDADE AGONISTA DE TLR4. A presente invenção refere-se a um composto que é útil como um adjuvante de vacina, um método para produzir o mesmo, uma composição farmacêutica que contém o composto, e uso do composto como um adjuvante de vacina.
BR112022025969A 2020-06-22 2021-06-21 Adjuvante com atividade agonista de tlr4 BR112022025969A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020107194 2020-06-22
PCT/JP2021/023402 WO2021261444A1 (ja) 2020-06-22 2021-06-21 Ｔｌｒ４作動活性を有するアジュバント

Publications (1)

Publication Number Publication Date
BR112022025969A2 true BR112022025969A2 (pt) 2023-01-17

Family

ID=79281148

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022025969A BR112022025969A2 (pt) 2020-06-22 2021-06-21 Adjuvante com atividade agonista de tlr4

Country Status (13)

Country Link
US (1) US20230287027A1 (pt)
EP (1) EP4169527A1 (pt)
JP (1) JPWO2021261444A1 (pt)
KR (1) KR20230026438A (pt)
CN (1) CN116056721A (pt)
AU (1) AU2021295796A1 (pt)
BR (1) BR112022025969A2 (pt)
CA (1) CA3187828A1 (pt)
CL (1) CL2022003689A1 (pt)
IL (1) IL299253A (pt)
MX (1) MX2022016181A (pt)
PE (1) PE20230463A1 (pt)
WO (1) WO2021261444A1 (pt)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
ES2370262T3 (es) 1999-11-15 2011-12-14 Oncothyreon Inc. Análogos del lípido a sintéticos y sus utilizaciones.
HUE026376T2 (en) 2003-01-06 2016-05-30 Corixa Corp Certain aminoalkyl glucosamide phosphate compounds and their use
WO2008147480A2 (en) 2007-02-01 2008-12-04 Panthera Biopharna, Llc. Hydroxamic acid derivatives of 3-phenyl propionic acids useful as thrapeutic agents for treating anthrax poisoning
WO2016109880A1 (en) * 2015-01-06 2016-07-14 Immunovaccine Technologies Inc. Lipid a mimics, methods of preparation, and uses thereof
KR20200123436A (ko) * 2018-02-12 2020-10-29 이니뮨 코퍼레이션 톨-유사 수용체 리간드

Also Published As

Publication number Publication date
EP4169527A1 (en) 2023-04-26
CA3187828A1 (en) 2021-12-30
US20230287027A1 (en) 2023-09-14
CN116056721A (zh) 2023-05-02
WO2021261444A1 (ja) 2021-12-30
PE20230463A1 (es) 2023-03-14
CL2022003689A1 (es) 2023-07-28
IL299253A (en) 2023-02-01
KR20230026438A (ko) 2023-02-24
AU2021295796A1 (en) 2023-02-02
MX2022016181A (es) 2023-02-13
JPWO2021261444A1 (pt) 2021-12-30

Similar Documents

Publication Publication Date Title
BR112022010112A2 (pt) Aminoquinolonas substituídas como inibidores de dgkalfa para ativação imunológica
DOP2016000047A (es) Compuestos y composiciones como inhibidores de la mek
BR112015023922A2 (pt) composição farmacêutica compreendendo um ativador de ampk e um agente serotonérgico e métodos de uso destes
BR112012030024A2 (pt) compostos, processo para a preparação de um composto, medicamento
BR112018011210A2 (pt) métodos para inibir a conversão de carnitina em trimetilamina (tma)
BR112017002214A2 (pt) composto de fórmula (i), composição farmacêutica e usos de um composto
ECSP099620A (es) Derivados de ciclohexano espirociclico
CU20200008A7 (es) Compuestos de dihidrooxadiazinonas sustituidas útiles en el tratamiento de enfermedades hiperproliferativas, métodos para preparar dichos compuestos y composiciones farmacéuticas que los contienen
BR112019025548A2 (pt) Inibição ou redução do crescimento de plantas por biocimentação
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
BR112017008312A2 (pt) novos compostos de piridopirimidinona para modular a atividade catalítica de histona lisina demetilases (kdms)
SV2017005466A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
BRPI0916069C1 (pt) composto, usos de um composto, composição farmacêutica, composição cosmética e usos cosméticos de uma composição
CO2019002523A2 (es) Inhibidores de dopamina–β–hidroxilasa penetrantes de la barrera hematoencefálica
BR112015032776A2 (pt) misturas de compostos e de álcoois, processos para a preparação de uma mistura de compostos e para a limpeza de superfícies duras ou fibras, uso de misturas de compostos, e, formulação aquosa
BR112017004991A2 (pt) compostos antimicrobianos de imidazólio
BR112023006312A2 (pt) Composto, métodos para preparar o composto, composição farmacêutica e uso do composto
BR112018077350A2 (pt) composições de fosfolipídio
CO2021011023A2 (es) Compuesto heterocíclico, composición farmacéutica que lo comprende, método para su preparación, y uso de estos
BR112017015744A2 (pt) composto apresentando uma estrutura de fórmula (i), um sal farmaceuticamente aceitável do mesmo ou um isômero ótico do mesmo, composição farmacêutica e uso do composto de fórmula (i) para o tratamento e prevenção de mycobacterium tuberculosis ou outras infecções microbianas
BR112023003744A2 (pt) Composto, e, composição farmacêutica para o tratamento de doenças associadas a diacilglicerol aciltransferase 2
BR112022012436A2 (pt) Formulação compósita e método para preparar a formulação compósita
BR112022009765A2 (pt) Composição para inibir produção de hmf que compreende dissacarídeo de alulose
BR112022015792A2 (pt) Inibidores de pad4 heterocíclicos
BR112022012368A2 (pt) Composto, e, composição farmacêutica para o tratamento de doenças associadas a diacilglicerol aciltransferase 2